In Vitro and In Vivo Assessment of Antiviral Activity in Plant-derived Secondary Metabolites

Julia Ruben^*
*Correspondence: Julia Ruben, Department of Biological Sciences, University of Bath, Claverton Down, Bath BA2 7AY, UK, Email:

Introduction

Plant-derived secondary metabolites have garnered significant attention for their potential as antiviral agents due to their diverse pharmacological properties and relatively low toxicity. Many of these compounds have been utilized in traditional medicine and are now being studied for their ability to combat various viral infections, including influenza, herpes simplex virus, hepatitis, and more recently, novel viral pathogens such as SARS-CoV-2. This article reviews the current state of research on the antiviral activity of plant secondary metabolites, with a particular focus on both in vitro and in vivo evaluations. We discuss the molecular mechanisms of action of key plantderived antiviral agents, methodologies used in the assessment of antiviral efficacy, and the challenges and opportunities associated with developing plant-based antiviral therapeutics.

Viral infections are responsible for a wide range of diseases, from the common cold to life-threatening conditions like HIV/AIDS, hepatitis, and COVID-19. Despite the availability of antiviral medications, challenges such as viral resistance, high costs, and adverse side effects have spurred interest in alternative treatments, including plant-derived secondary metabolites. Secondary metabolites are non-essential compounds produced by plants that have diverse biological activities, including antimicrobial, anti-inflammatory, and antiviral properties. Many of these compounds are used in traditional medicine, and scientific studies have increasingly focused on their antiviral potential.

In vitro and in vivo models are essential tools for assessing the antiviral properties of plant-derived compounds. In vitro studies allow for the precise evaluation of antiviral activity under controlled conditions, while in vivo models provide insights into the pharmacokinetics, efficacy, and safety of these compounds in a living organism. This review explores the antiviral activity of plant-derived secondary metabolites, highlighting their mechanisms of action, the methodologies used in antiviral assessments, and the challenges involved in translating these compounds from laboratory studies to clinical application. Plant secondary metabolites exhibit antiviral activity through several mechanisms, which can be broadly categorized into inhibition of viral entry, replication, and assembly, as well as immune modulation. The first step in the viral life cycle is attachment and entry into host cells. Several plant secondary metabolites, particularly flavonoids and alkaloids, have been shown to block the binding of viruses to host cell receptors or interfere with the fusion of viral particles with the cell membrane

Compounds such as quercetin, kaempferol, and luteolin, which are found in fruits, vegetables, and herbs, have demonstrated the ability to inhibit viral attachment. For example, quercetin has been shown to prevent the entry of respiratory syncytial virus into host cells by interacting with the viral envelope glycoproteins, thereby blocking viral fusion. Alkaloids like berberine (from Berberis spp.) and ephedrine (from Ephedra spp.) have also been shown to interfere with viral binding and entry. Berberine, in particular, has been reported to inhibit the entry of herpes simplex virus by blocking the interaction between the virus and host cell surface receptors. After entering the host cell, viruses replicate their genomes and produce new viral particles. Several plant metabolites inhibit viral replication by targeting viral enzymes involved in genome replication, such as reverse transcriptase in retroviruses and RNA polymerase in RNA viruse

Polyphenolic compounds like resveratrol (from Vitis vinifera) and catechins (from Camellia sinensis, i.e., green tea) are known to inhibit viral replication. Resveratrol has been shown to inhibit HIV-1 replication by preventing the activation of the nuclear factor-kappa B (NF-κB) pathway, which is essential for viral replication. Some terpenoids, such as ursolic acid (from Rosmarinus officinalis) and limonene (from citrus fruits), have been shown to inhibit the replication of viruses such as the hepatitis C virus and the human papillomavirus by interfering with viral RNA synthesis or inhibiting viral proteases. After replication, viruses must assemble new viral particles and release them from infected cells. Certain plant-derived compounds can block these final stages of the viral life cycle.

Description

These compounds, found in a variety of plants including Glycyrrhiza glabra (licorice), have been shown to prevent viral assembly and release. Glycyrrhizin, a triterpenoid saponin, has been extensively studied for its inhibitory effect on the replication and release of viruses, including the SARS-CoV virus. It inhibits viral protein expression and can interfere with the viral budding process. In addition to direct antiviral activity, many plantderived compounds exert immunomodulatory effects, boosting the host’s immune response and helping to combat viral infections. For example, certain flavonoids, such as apigenin and genistein, are known to enhance the activity of immune cells like macrophages and T-cells, and can also increase the production of cytokines like interferons, which play a critical role in antiviral immunity [1-3].

In vitro studies are a cornerstone of antiviral research, as they provide initial evidence for the efficacy and mechanism of action of plant-derived compounds. Several methods are used to assess antiviral activity in cell cultures, including cytotoxicity assays, plaque reduction assays, viral yield reduction assays, and RT-PCR-based viral load quantification. Before testing antiviral activity, it is crucial to evaluate the cytotoxicity of the plant-derived compounds to ensure they are not toxic to host cells. Common assays include the MTT assay and the CellTiter-Glo assay, which measure cell viability by assessing mitochondrial activity or ATP levels, respectively.

This assay measures the ability of a compound to reduce the number of viral plaques formed on a monolayer of host cells. The presence of viral plaques indicates successful infection, and the reduction in the number of plaques reflects antiviral activity. These assays measure the reduction in the amount of virus released from infected cells after treatment with the plantderived compound. Quantification of viral load is typically performed using enzyme-linked immunosorbent assays, quantitative PCR, or viral protein detection. RT-PCR and quantitative RT-PCR are frequently used to quantify viral RNA levels in treated cells. This allows researchers to assess the ability of plant metabolites to inhibit viral replication at the transcriptional level. In vivo studies are critical for confirming the therapeutic potential and safety of antiviral compounds identified in vitro. Animal models are used to evaluate the pharmacokinetics, bioavailability, and therapeutic efficacy of plant-derived antiviral agents.

Mouse models are commonly employed to assess the efficacy of antiviral compounds. For example, Cavia porcellus (guinea pigs) or Mus musculus (mice) are infected with viruses like influenza or HSV, and the antiviral activity of the plant compound is assessed by measuring viral load, survival rates, and clinical signs of disease after treatment. In studies on resveratrol, mice infected with the influenza virus were treated with resveratrol, resulting in reduced viral replication and improved survival rates. In vivo studies also provide critical information about the pharmacokinetics (absorption, distribution, metabolism, and excretion) of plant-derived antiviral agents. Animal models can be used to assess how the compound is metabolized and whether it reaches effective concentrations at the site of infection without causing toxic effects. Many plant metabolites suffer from poor solubility and low bioavailability, which limits their therapeutic potential. Nanotechnology, lipid-based formulations, and chemical modifications are being explored to overcome these limitations. Despite being natural, some plant compounds can be toxic at high doses [4,5]. Careful evaluation of dose-response relationships and long-term safety is necessary.

The efficacy of plant-based antivirals can vary depending on factors such as the plant’s geographical origin, harvest time, and preparation methods. Standardization of plant extracts and active compounds is critical for ensuring consistent efficacy in clinical applications. Just like synthetic antiviral drugs, natural products may face challenges from the development of viral resistance. Continuous monitoring of resistance patterns and the exploration of combination therapies may be necessary.

Conclusion

Plant-derived secondary metabolites represent a promising source of antiviral agents, with the potential to combat a wide range of viral infections. In vitro and in vivo studies have elucidated various mechanisms of action, including viral entry inhibition, replication inhibition, immune modulation, and viral assembly disruption. However, challenges such as bioavailability, toxicity, and viral resistance must be addressed to maximize the clinical potential of these compounds. Continued research into plant-based antivirals, including the development of novel delivery systems and combination therapies, will be essential for advancing these natural products into viable therapeutic options.

Acknowledgment

None.

Conflict of Interest

None.

References

1. Kumar, Rohit, Yogendra Kumar Gupta, Surender Singh and Arun Raj. "Anti-inflammatory effect of Picrorhiza kurroa in experimental models of inflammation." Planta Med 82 (2016): 1403-1409.

Google Scholar, Crossref, Indexed at

2. Kariu, Toru, Ryoma Nakao, Tsuyoshi Ikeda and Keisuke Nakashima, et al. "Inhibition of gingipains and Porphyromonas gingivalis growth and biofilm formation by prenyl flavonoids." J Periodontal Res 52 (2017): 89-96.

Google Scholar, Crossref, Indexed at

3. Asgarpanah, Jinous, Seyyed Jamal Hashemi, Elham Hashemi and Kiana Askari. "In vitro antifungal activity of some traditional Persian medicinal plants on pathogenic fungi." Chin J Integ Med 23 (2017): 433-437.

Google Scholar, Crossref, Indexed at

4. Fischer, Felix H., George Lewith, Claudia M. Witt and Klaus Linde, et al. "High prevalence but limited evidence in complementary and alternative medicine: Guidelines for future research." BMC Complement Med Ther 14 (2014): 1-9.

Google Scholar, Crossref, Indexed at

5. Poudiougou, Oumar, Pierre-Emile Bruand, Pakuy Pierre Mounkoro and Jean-Michel Gaglione, et al. "Mental health capacity building in Mali by training rural general practitioners and raising community awareness." Pan Afr Med 38 (2021).

Google Scholar, Crossref, Indexed at